Skip to content

Symbicort

DRUG14 trials

Sponsors

Astrazeneca AB, AstraZeneca AB, AstraZeneca, Stanford University, Maisonneuve-Rosemont Hospital

Conditions

AsthmaAsthma, AllergicBronchiectasisBronchiolitis ObliteransCOPDCOPD PatientsChronic Obstructive Lung DiseaseCryptogenic Organizing Pneumonia

Phase 2

Phase 3

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
CompletedNCT01360021
AstraZenecaAsthma
Start: 2011-11-30End: 2012-08-31Updated: 2014-03-11
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
CompletedNCT02157935
AstraZenecaCOPD Patients
Start: 2014-06-27End: 2016-02-08Updated: 2017-11-07
Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients
CompletedNCT03015259
Kindeva Drug DeliveryAsthma
Start: 2016-12-29End: 2018-02-08Updated: 2022-08-24
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
CompletedNCT03468790
Shanghai Biomabs Pharmaceutical Co., Ltd.Asthma, Allergic
Start: 2018-05-09End: 2021-03-09Updated: 2021-10-11
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressurised MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)
CompletedCTIS2023-505787-11-00
AstraZeneca ABSevere and inadequately controlled asthma
Start: 2021-04-29End: 2025-03-18Target: 678Updated: 2025-05-05
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
CompletedCTIS2023-505786-88-00
Astrazeneca ABSevere and inadequately controlled asthma
Start: 2021-04-25End: 2025-03-19Target: 441Updated: 2025-03-21
A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler® in Participants with Inadequately Controlled Asthma (VATHOS)
CompletedCTIS2024-513568-24-00
AstraZeneca ABInadequately Controlled Asthma
Start: 2022-03-23End: 2025-02-12Target: 160Updated: 2025-02-20

Phase 4

Unknown Phase

Related Papers